- Home
- AFRI vs ABEO Comparison
AFRI vs ABEO Comparison
Compare AFRI & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AFRI
- ABEO
- Stock Information
- Founded
- AFRI 1943
- ABEO N/A
- Country
- AFRI Gibraltar
- ABEO United States
- Employees
- AFRI N/A
- ABEO N/A
- Industry
- AFRI Packaged Foods
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- AFRI Consumer Staples
- ABEO Health Care
- Exchange
- AFRI Nasdaq
- ABEO Nasdaq
- Market Cap
- AFRI 278.3M
- ABEO 277.6M
- IPO Year
- AFRI N/A
- ABEO 1980
- Fundamental
- Price
- AFRI $10.35
- ABEO $5.98
- Analyst Decision
- AFRI
- ABEO Strong Buy
- Analyst Count
- AFRI 0
- ABEO 3
- Target Price
- AFRI N/A
- ABEO $18.00
- AVG Volume (30 Days)
- AFRI 7.6K
- ABEO 349.0K
- Earning Date
- AFRI 12-23-2024
- ABEO 11-14-2024
- Dividend Yield
- AFRI N/A
- ABEO N/A
- EPS Growth
- AFRI N/A
- ABEO N/A
- EPS
- AFRI N/A
- ABEO N/A
- Revenue
- AFRI $305,476,000.00
- ABEO N/A
- Revenue This Year
- AFRI N/A
- ABEO N/A
- Revenue Next Year
- AFRI N/A
- ABEO $7,097.06
- P/E Ratio
- AFRI N/A
- ABEO N/A
- Revenue Growth
- AFRI 5.42
- ABEO 147.52
- 52 Week Low
- AFRI $9.63
- ABEO $3.05
- 52 Week High
- AFRI $12.00
- ABEO $9.01
- Technical
- Relative Strength Index (RSI)
- AFRI 47.91
- ABEO 45.43
- Support Level
- AFRI $10.02
- ABEO $5.62
- Resistance Level
- AFRI $10.55
- ABEO $6.01
- Average True Range (ATR)
- AFRI 0.30
- ABEO 0.31
- MACD
- AFRI 0.01
- ABEO -0.05
- Stochastic Oscillator
- AFRI 28.15
- ABEO 31.03
About AFRI Forafric Global PLC
Forafric Global PLC is engaged in production and sale of a variety of wheat flours, Semolina and Pasta and Couscous in Morocco and in more than 45 countries. The two main brands in Morocco are MAYMOUNA and TRIA. The company derives majority of its revenue from Soft wheat.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.